ADMA Biologics Inc (ADMA) Insider Adam S. Grossman Buys 30,000 Shares

ADMA Biologics Inc (NASDAQ:ADMA) insider Adam S. Grossman bought 30,000 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The stock was purchased at an average cost of $4.00 per share, for a total transaction of $120,000.00. Following the completion of the transaction, the insider now directly owns 37,527 shares in the company, valued at approximately $150,108. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ ADMA opened at $4.70 on Thursday. ADMA Biologics Inc has a 12-month low of $2.08 and a 12-month high of $6.96. The firm has a market capitalization of $201.17 million, a P/E ratio of -3.24 and a beta of 3.05. The company has a debt-to-equity ratio of 5.70, a current ratio of 4.60 and a quick ratio of 2.39.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, March 13th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.06). ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%. The company had revenue of $4.06 million during the quarter, compared to analyst estimates of $5.19 million. On average, analysts forecast that ADMA Biologics Inc will post -1.24 earnings per share for the current year.

Several research analysts recently weighed in on the company. ValuEngine raised ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. WBB Securities raised ADMA Biologics to a “buy” rating in a research report on Thursday, April 4th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price (up from $10.00) on shares of ADMA Biologics in a research report on Monday, April 15th. Maxim Group set a $12.00 target price on ADMA Biologics and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Finally, Oppenheimer increased their target price on ADMA Biologics from $14.00 to $16.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 2nd. Nine research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $11.42.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Diag Capital Management LP acquired a new position in shares of ADMA Biologics during the fourth quarter worth approximately $435,000. JPMorgan Chase & Co. lifted its stake in ADMA Biologics by 54.7% in the third quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock valued at $1,422,000 after acquiring an additional 81,003 shares during the last quarter. Delek Group Ltd. lifted its stake in shares of ADMA Biologics by 102.5% during the 4th quarter. Delek Group Ltd. now owns 118,539 shares of the biotechnology company’s stock worth $291,000 after buying an additional 60,000 shares during the last quarter. BlackRock Inc. lifted its stake in shares of ADMA Biologics by 0.5% during the 4th quarter. BlackRock Inc. now owns 964,349 shares of the biotechnology company’s stock worth $2,305,000 after buying an additional 4,577 shares during the last quarter. Finally, Vanguard Group Inc lifted its stake in shares of ADMA Biologics by 5.2% during the 3rd quarter. Vanguard Group Inc now owns 1,192,641 shares of the biotechnology company’s stock worth $7,406,000 after buying an additional 58,610 shares during the last quarter. Hedge funds and other institutional investors own 52.51% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “ADMA Biologics Inc (ADMA) Insider Adam S. Grossman Buys 30,000 Shares” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.wkrb13.com/2019/05/23/adma-biologics-inc-adma-insider-adam-s-grossman-buys-30000-shares.html.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Further Reading: Intrinsic Value

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.